Can Fite Biopharma stock hits 52-week low at $1.22

Published 14/04/2025, 20:04
Can Fite Biopharma stock hits 52-week low at $1.22

Can Fite Biopharma Ltd (NYSE American: NYSE:CANF) stock has reached a new 52-week low, touching down at $1.22, significantly below its 52-week high of $4.69. According to InvestingPro data, analysts maintain a positive outlook with price targets ranging from $10 to $18. This latest price movement reflects a continued downtrend for the biopharmaceutical company, which specializes in developing innovative treatments for severe medical conditions. Over the past year, Can Fite’s stock has experienced a significant decline, with a 1-year total return of -25.24%. While the company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 2.93, InvestingPro analysis reveals rapid cash burn and declining sales expectations. Investors are closely monitoring the company’s progress and potential catalysts that may influence future stock performance. Get access to 6 additional InvestingPro Tips and comprehensive financial analysis to make more informed investment decisions.

In other recent news, Can-Fite BioPharma has announced a registered direct offering of its American Depositary Shares (ADSs), aiming to raise $3 million before fees and expenses. The company has agreed to sell 2.5 million ADSs at a price of $1.20 each, with the offering facilitated by H.C. Wainwright & Co. as the exclusive placement agent. The proceeds from this offering are intended for research and development, clinical trials, working capital, and general corporate purposes. The offering is expected to close soon, pending customary closing conditions. This development follows the company’s effective shelf registration statement on Form F-3, filed earlier in September and declared effective by the U.S. Securities and Exchange Commission. Can-Fite’s lead drug candidate, Piclidenoson, has shown positive results in a Phase III trial for psoriasis and is currently in a pivotal Phase III trial. Another drug, Namodenoson, is undergoing various stages of clinical trials for several conditions and has received Orphan Drug and Fast Track Designations by the FDA. Additionally, their drug candidate CF602 has demonstrated efficacy in treating erectile dysfunction.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.